Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in KMK?
Kromek Group PLC: THE INVESTMENT CASE

Kromek expects revenues to jump this year as demand continues to grow

The radiation detection specialist is expecting revenues to grow by at least 40% this year after spending a couple of years laying the foundations
x-ray image
INVESTMENT OVERVIEW: KMK The Big Picture
Kromek’s technology can be applied to the medical, nuclear or security screening markets

Earlier this year, Kromek Group PLC (LON:KMK) said it was seeing increasing interest in its radiation detection technologies, and if recent contract wins are anything to go by, it certainly wasn’t overegging the pudding.

The company – whose technology is used in everything from screening for cancers to sniffing out nuclear devices – has won several large contracts in recent months.

New multi-years, multi-million pound contracts

Only last month it bagged a five-year contract worth US$5.38mln with an existing customer which will incorporate its cadmium zinc telluride (CZT)-based detector modules into a new medical diagnostics product.

READ: Kromek lands five-year contract worth at least US$5.38mln

READ: Kromek bags another multi-year, multi-million pound contract

It followed that up with another five-year, US$2mln agreement with a new customer which will use its technology in its baggage security screening systems.

“This agreement further demonstrates the demand for our products and technology as all OEMs in this arena begin upgrading their legacy systems to bring them in line to detect modern day threats,” said chief executive Arnab Basu.

That's on top of several other decent contracts secured earlier in the year, including a US$3.1mln security screening deal with an unnamed US customer in the homeland security marketplace.

High performance radiation detection

The company is the developer of high performance radiation detection products based on cadmium zinc telluride (CZT) and other advanced technologies.

Using its core platforms, Kromek designs, develops and produces x-ray and gamma photon imaging and radiation detection products for the medical, security screening and nuclear markets.

They provide high resolution information on material composition and structure.

This means they can be used in many applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek operates a vertically integrated technology. What this means practically is it offers customers core technology components as well finished products such detectors, including software, electronics and application specific integrated circuits.

While based in the north-east, the business, which employs 100, has operations in California and Pennsylvania and sells internationally through distributors and direct to manufacturers.

Companies moving towards CZT technology

As Basu alluded to, the message from Kromek is that more and more companies are looking to move away from traditional detector technology to CZT.

Compared to the likes of silicon and germanium detectors, CZT operates at room temperature and can process more than 10mln photons / second / mm^2 (that’s a good thing).

“The unique combination of spectroscopy and very high count rate capability at room temperature makes CZT an ideal detector solution for Medical, Industrial, Homeland Security and Laboratory applications,” the Kromek website reads.

Starting to benefit from hard work over past couple of years

Back in April, Kromek predicted a “step-change” in revenue growth given the increasing demand it is now seeing for its products.

The Durham-headquartered group is expecting revenues to grow by at least 40% this year, reaping the rewards of two years’ worth of hard work during which it has been laying the foundations.

READ: Kromek undergoing commercial transformation...

READ: Kromek raises £21mln...

WATCH: Boss 'very pleased' with fundraise...

In January it raised £21mln from investors which has allowed it to tap into the huge market opportunities and to invest in research and development, which keeps the company at the cutting edge of radiation technology.

In the year ended April 30 Kromek generated revenues of £8.7mln, up from £8.3mln. As might be expected from a business setting out on the commercial phase of its development, it was loss-making – to the tune of £1.5mln.

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

Jobs market
September 19 2017
A flexible jobs market, an increase in short-term contracts - all play to the strengths of the specialist in background checks
Tekcapital-Invention-Discovery-Network-(IDN)-June-2015_opt.jpg
July 31 2017
The firm has established connections with more than 4,000 universities in 160 countries enabling it to capture all of the intellectual property available
picture of virtual reality headset
October 24 2017
New shares sold through a book build exercise in about two hours at a tiny discount to the market price to rasie £75mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use